The Company's API site at Changzhou underwent a GMP surveillance inspection by the FDA that began on March 4. Covering 21 FDA ...

Developing a small molecule active pharmaceutical ingredient (API) is often a risky process. Reaching the goal, be it first in human studies or commercial manufacture, requires data and material ...

Saint-Beauzire Facility Saint-Beauzire Production Line for both liquid and lyophilized forms BUBENDORF, Switzerland, March 24 ...

Carbogen Amcis has been granted a GMP certificate for its 9,500m² Saint-Beauzire facility, supporting a wide range of ...

The USFDA inspection was conducted from March 17 to 21 at the Alembic Pharma API-III facility located at Karakhadi.

BUBENDORF, Switzerland, March 24, 2025 (GLOBE NEWSWIRE) -- Switzerland-based CARBOGEN AMCIS, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing ...

BUBENDORF, Switzerland, March 24, 2025 (GLOBE NEWSWIRE) -- Switzerland-based CARBOGEN AMCIS, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing ...